From the Journals: Editors’ Picks for May
Every month, the editors from the eight AACR journals select one “must read” article from each issue, which we...
Category: AACR
Every month, the editors from the eight AACR journals select one “must read” article from each issue, which we...
Shenzhen is a remarkable place. It serves as a gateway to Hong Kong, and in its short 40-year history...
Greetings from Shenzhen, China, where the Fifth AACR New Horizons in Cancer Research (NHiCR) Conference is now underway. The event’s...
As a regular feature on this blog, we spotlight 10 “must read” articles selected by our editors from each...
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
Over the course of AACR Annual Meeting 2019, there were 213 presentations on incredibly exciting clinical trials. This is...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...